Sunshine Lake Pharma Lists on HKEX via Introduction Method
China-based Sunshine Lake Pharma Co., Ltd. (HKG: 6887) has successfully listed on the Main Board...
HKG: 1558
YiChang HEC’s Yiqibuvir Approved by NMPA for Chronic HCV Infection
China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG: 1558) announced receiving marketing approval from the...
YiChang HEC ChangJiang Pharmaceutical and DP Technology Deepen Partnership with AI Focus
China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced a comprehensive partnership with...
Sunshine Lake Pharma Inks Licensing Deal with Apollo Therapeutics for APL-18881
China-based Sunshine Lake Pharma Co., Ltd., (HKG: 1558) a member of the HEC Group, has...
China’s Insulin Volume-Based Procurement Tender Results Renewed with 17% Higher Contracted Value
The renewal of winning bids from the insulin volume-based procurement (VBP) tender, initially held in...
YiChang HEC ChangJiang Pharmaceutical’s Yiqibuvir Receives NMPA Review for Hepatitis C Treatment
China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced that the National Medical...
YiChang HEC ChangJiang Pharmaceutical Reports 309.83% YOY Revenue Growth in 2022 Financials
YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558), a China-based pharmaceutical company, has released its...
YiChang HEC ChangJiang Pharma’s Insulin Aspart Gains NMPA Approval
China-based firm YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced that its in-house...
YiChang HEC Reports Strong Recovery in 2022 Interim Results
China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has released its 2022 interim report,...